EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance
{{output}}
The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understandi... ...
